@misc{Dulak_Józef_Gene_2000,
 author={Dulak, Józef},
 volume={48},
 number={1},
 copyright={Creative Commons Attribution BY-SA 4.0 license},
 journal={Biotechnologia, vol.48, 1 (2000)-.},
 howpublished={online},
 year={2000},
 publisher={Committee on Biotechnology PAS},
 publisher={Institute of Bioorganic Chemistry PAS},
 language={pol},
 abstract={Gene therapy is suggested to be beneficial for the treatment of diseases whichare difficult or impossible to be cured by classical pharmacotherapy. Thus, the transfer of genetic material of potential therapeutic properties may be particularly helpfulin the treatment of hereditary genetic disorders and cancer. However, serious technical obstacles, especially the lack of efficient vectors for the delivery oftherapeutic genes have so far prevented the achievement of convincing therapeutic effects. On theother hand, the complications of atherosclerosis, such as heart or peripheral ischaemia, seem to be good candidates for genetic strategies aimed particularly at stimulation of angiogenesis. As in this case therapeutic genes should be expressed locallyand in a short time there is a good chance that the application ofthis therapy will takeplace earlier than in the case of other disorders. In this paper the first gene therapyclinical trials in human cardiovascular diseases are described. The latest investigationson the basic mechanisms of the blood vessel wall physiology and relationships between factors involved in angiogenesis are also briefly mentioned},
 title={Gene therapy of cardiovascular diseases},
 type={Text},
 URL={http://www.rcin.org.pl/Content/142201/PDF/POZN271_177570_biotechnologia-2000-no1-dulak.pdf},
 keywords={biotechnology},
}